210579-45-6

Basic information

• Product Name: Butanoic acid, 2-[(3-nitrophenyl)methylene]-3-oxo-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl ester
• CAS NO: 210579-45-6
• Molecular Formula: C31H34N2O5
• Molecular Weight: 514.621
• Mol File: 210579-45-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 2-[(3-nitrophenyl)methylene]-3-oxo-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-[(3-nitrophenyl)methylene]-3-oxo-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl ester(210579-45-6)
• EPA Substance Registry System: Butanoic acid, 2-[(3-nitrophenyl)methylene]-3-oxo-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl ester(210579-45-6)

Safety Data

• Hazardous Substances Data: 210579-45-6(Hazardous Substances Data)

Upstream product

• 28075-29-8 N-methyl-3,3-diphenylpropylamine 
• 100442-33-9 2,N-dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol 
• 99-61-6 3-nitro-benzaldehyde 
• 100427-51-8 1,1,N-trimethyl-N-(3,3-diphenylpropy)-2-aminoethyl acetoacetate 

Downstream Products

• 786625-22-7 2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-{2-[(3,3-diphenyl-propyl)-methyl-amino]-1,1-dimethyl-ethyl} ester 5-ethyl ester 
• 100427-26-7 lercanidipine 

Relevant articles and documents

Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6- dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenylpropylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4- dihydropyridines binding site labelled by 3H-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375- lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries.